People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atsena Therapeutics, Inc. | — | Biotechnology | Series C | $146.0M | $605.7M | 2023 |
| Nido Biosciences, Inc. | — | Biotech / Pharma | Series B | $22.4M | $636.4M | 2020 |
| Brave Bio, Inc. | — | Biotech / Pharma | Series A | $5.3M | $99.6M | 2021 |
Jacqueline Grant at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jacqueline Grant on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Andrew Schwab | 1 | 16 |
| James Healy | 1 | 8 |
| Meredith Fisher | 1 | 6 |
| Andrew Hedin | 1 | 5 |
| Norbert Riedel | 1 | 4 |
| Michael Dial | 1 | 4 |
| Jamil Beg | 1 | 2 |
| Benjamin Yerxa | 1 | 2 |
| Elliot Ehrich | 1 | 2 |
| Patrick Ritschel | 1 | 2 |
| Joe Zakrzewski | 1 | 1 |
| Jennifer Wellman | 1 | 1 |
| Christina Isacson | 1 | 1 |
| Shannon Boye | 1 | 1 |
| Elizabeth Leiderman | 1 | 1 |
| Sanford Boye | 1 | 1 |
| Chris Carpenter | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.